Trial Profile
Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Aug 2022
Price :
$35
*
At a glance
- Drugs TRPH 222 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Triphase Accelerator Corporation
- 13 May 2022 Status changed from recruiting to completed.
- 22 Feb 2022 Updated preliminary results (n=32, as of January 7, 2022) published in the Triphase Accelerator Corporation media release.
- 08 Dec 2020 Results (cut-off date-30 Jun 2020) of dose-esclalation presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology